Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial

BACKGROUND: Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled efficacy data from six phase 2 trials, therapy using 3,4-methylenedioxymethamphetamine (MDMA) appeared cost-saving from a payer’s perspective. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Marseille, Elliot, Mitchell, Jennifer M., Kahn, James G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880875/
https://www.ncbi.nlm.nih.gov/pubmed/35213554
http://dx.doi.org/10.1371/journal.pone.0263252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880875/
https://www.ncbi.nlm.nih.gov/pubmed/35213554
http://dx.doi.org/10.1371/journal.pone.0263252

Ejemplares similares